A. C. Zorrilla

Combination of metformin plus TKI vs. TKI alone in EGFR(+) LUNG adenocarcinoma: A randomized phase II study.

M. Jiménez, F. Barrón, L. Ramírez-Tirado, 2018 .

Outcomes in Latin American NSCLC patients harboring wild-type or activating mutations of EGFR (CLICaP Registry).

R. Rosell, A. Campos-Parra, O. Arrieta, 2012 .

Distribution and impact of research in hematology and oncology in Latin America (LATAM): A decade of uncertainty (ONCOLGroup).

L. Reveiz, C. Vargas, J. Otero, 2012 .

Integrated genomic analysis by whole exome and transcriptome sequencing of tumor samples from EGFR-mutant non-small-cell lung cancer (NSCLC) patients (p) with acquired resistance to erlotinib.

J. Weissman, R. Stahel, A. Uzilov, 2013 .

Effect of immunotherapy at any line of treatment on survival in Hispanic patients with advanced metastatic non-small cell lung cancer (NSCLC) compared with chemotherapy (Quijote-CLICaP).

R. Rosell, C. Rolfo, L. Raez, 2019, Journal of Clinical Oncology.

198TiP Afatinib plus EGF pathway targeting immunization (EGF-PTI) as first line therapy for EGFR mutant NSCLC: The EPICAL study

E. D'hondt, N. Karachaliou, D. Rodríguez-Abreu, 2018 .